This afternoon, OssDsign released preliminary Q1 figures.
Redeye briefly comments on ExpreS2ion’s announcement of a published Hong Kong patent application cov...
Last Wednesday, Redeye hosted an investor forum. Redeye Investor Forum was a live broadcast in which...
Duell’s sales were flat organically and ahead of our and FactSet consensus expectations in Q2, while...
* Xplora has the tools to drive a good senior conversion rate * We forecast a ~30% EBITA CAGR from '...
Redeye is positive on Senzime’s secured contracts with one of the world’s largest IDNs.
Xplora's monthly subscriptions update shows that the Xplora Kids subscriber base for Q1 2026 ended a...
Mendus has announced the launch of its chronic myeloid leukaemia (CML) programme for lead immunother...
Redeye shares its preview of Xvivo’s Q1 2026 results, due on April 24.
Acast är en svensk poddplattform som effektivt kopplar samman poddare och annonsörer.
Duell issued a profit warning yesterday ahead of its Q2 note, significantly lowering guidance for bo...
* Memory prices could cause pre-buying in H1 and setback thereafter * Good earnings resilience, 8% a...
Redeye comments on EG7’s announcement of a potential acquisition of Cold Iron which looks well-struc...
Skiftet mot återkommande intäkter lägger grunden för en högt skalbar affärsmodell.
Duell announced a profit warning today due to continued weak performance in France, while winter sal...
Redeye terminates its coverage of Devyser Diagnostics and will cease providing research following qu...
Redeye comments on Alzinova’s announcement of a new research collaboration with Amsterdam UMC aimed ...
Redeye expects a broadly stable Q1 2026 report from Addnode, with acquisition-driven growth across D...
* Relatively light comps in Q1e, but market still tough * We raise '26e-'28e EBIT by 1-3% * Trading ...
